US Stock MarketDetailed Quotes

PRRUF IMMUTEP LTD

Watchlist
  • 0.204
  • 0.0000.00%
15min DelayClose Nov 12 16:00 ET
296.66MMarket Cap-9.27P/E (TTM)

About IMMUTEP LTD Company

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Company Profile

SymbolPRRUF
Company NameIMMUTEP LTD
Listing DateApr 16, 2012
Founded1987
CEOMr. Marc Voigt
MarketPink Market
Employees44
Fiscal Year Ends06-30
AddressAustralia Square,264 George Street,Level 32, Suite 32.07
CitySydney
ProvinceNew South Wales (NSW)
CountryAustralia
Zip Code2000
Phone61-2-8315-7003
Websitehttp://www.immutep.com

Company Executives

  • Name
  • Position
  • Salary
  • Marc Voigt
  • Director, Chief Executive Officer and Chief Financial Officer
  • 1.06M
  • Professor Dr. Frederic Triebel, M.D.
  • Executive Director and Chief Scientific Officer
  • 864.44K
  • Dr. Florian Vogl, M.D.,PhD
  • Chief Medical Officer
  • 955.82K
  • Deanne Miller
  • Chief Operating Officer, General Counsel and Company Secretary
  • 565.23K
  • Dr. Russell J. Howard, PhD
  • Chairman of the Board
  • 222.02K
  • Pete A. Meyers
  • Deputy Chairman of the Board
  • 138.71K
  • Lis Boyce
  • Independent Director
  • 144.76K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
XINGANJIANG
873167
+30.00%
INNOVATIVE DATA
835305
+29.98%
CHENGUANG MEDICAL
430300
+29.96%
4
Hangzhou Gaoxin Materials Technology
300478
+20.04%
5
Beijing Philisense Technology
300287
+20.03%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Trump's comeback to the Office
Following Trump's Policies to Seek Investment Opportunities
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More
TSLA earnings preview: Grab rewards by guessing the opening price!